Information Provided By: 
Fly News Breaks for May 31, 2018
INFI
May 31, 2018 | 06:43 EDT
Seaport Global analyst Corey Davis initiated Infinity Pharmaceuticals with a Buy and $4 price target. The analyst believes 2018 could be a "break-out" year with new data on its lead compound IPI-549 in combination with Opdivo for various tumor types with June 4 at ASXO form its "dose escalation" cohort, Q2 initial data from the "dose expansion" cohort, and more mature data from the "dose expansion" later in the year.
News For INFI From the Last 2 Days
There are no results for your query INFI
